Apera Asset Management (“Apera”), a pan-European private debt investor in the midmarket space, is pleased to announce that it has arranged debt facilities to support Essling Capital’s acquisition of Teknimed, a leading French manufacturer of biomaterials used in orthopaedic and spine surgeries.
Founded in 1990, Teknimed is a French manufacturer of bone cements and substitutes, biodegradable implants and related instruments for orthopaedic and spine surgery. The company serves major players in the orthopaedic industry through its wide and diversified offering and is recognised for the high quality of its products.
Rémi Matuchansky, co-head Lead Investment at Essling Capital, said: “We have very much enjoyed working with the Apera investment team. Apera’s bespoke financing solutions will enable Teknimed to embark on the next step of its growth journey.”
Franklin Henrot, Partner at Apera, said: “We have very much enjoyed working with Essling on this first joint transaction. Teknimed is a leading biomaterials manufacturer supported by an experienced management team. We are pleased to be supporting the Company’s development and look forward to working with Essling Capital and management in Teknimed’s next phase of growth.”
Download a PDF of the press release here.
Apera Asset Management LLP is authorised and regulated by the Financial Conduct Authority (FRN: 771080).
Apera Asset Management LLP is incorporated in the UK and the registered office is at 33 Cavendish Square, London, W1G 0PW, United Kingdom.
The services of Apera Asset Management LLP are only available to professional clients and eligible counterparties. They are not available to retail clients.
Copyright Apera Asset Management ©2025. All rights reserved.
